FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119183208> ?p ?o ?g. }

• W2119183208 endingPage "212" @default.
• W2119183208 startingPage "205" @default.
• W2119183208 abstract "PurposeReview patterns of recurrence for Stage II endometrial cancer in a community practice.Methods and MaterialsA retrospective review of patients with endometrial cancer diagnosed between 1985–2002. Patients were excluded for Stages I, III, or IV or treatment with preoperative pelvic radiation (external beam radiation therapy [EBRT]).ResultsEighty-six patients with a mean follow-up of 70 months are reported. Higher risk patients were selected for adjuvant radiation with no apparent differences for those receiving only EBRT compared with EBRT with brachytherapy. Five-year actuarial vaginal, pelvic sidewall/nodal, and metastatic control rates were 100% and 100%, 96.9% and 100%, and 79% and 84.2% for patients receiving EBRT or EBRT with brachytherapy. Overall survival rates were 70.5% and 75.8%, and cause-specific survival rates were 78.8% and 82.9% for those receiving EBRT or EBRT with brachytherapy. A select group was observed and experienced one vaginal recurrence with overall and cause-specific survival rates of 100%.ConclusionIn higher risk patients with Stage II, adjuvant EBRT achieves excellent vaginal and pelvic sidewall/nodal control without apparent benefit from additional brachytherapy. Select patients may not require adjuvant treatment. Review patterns of recurrence for Stage II endometrial cancer in a community practice. A retrospective review of patients with endometrial cancer diagnosed between 1985–2002. Patients were excluded for Stages I, III, or IV or treatment with preoperative pelvic radiation (external beam radiation therapy [EBRT]). Eighty-six patients with a mean follow-up of 70 months are reported. Higher risk patients were selected for adjuvant radiation with no apparent differences for those receiving only EBRT compared with EBRT with brachytherapy. Five-year actuarial vaginal, pelvic sidewall/nodal, and metastatic control rates were 100% and 100%, 96.9% and 100%, and 79% and 84.2% for patients receiving EBRT or EBRT with brachytherapy. Overall survival rates were 70.5% and 75.8%, and cause-specific survival rates were 78.8% and 82.9% for those receiving EBRT or EBRT with brachytherapy. A select group was observed and experienced one vaginal recurrence with overall and cause-specific survival rates of 100%. In higher risk patients with Stage II, adjuvant EBRT achieves excellent vaginal and pelvic sidewall/nodal control without apparent benefit from additional brachytherapy. Select patients may not require adjuvant treatment." @default.
• W2119183208 created "2016-06-24" @default.
• W2119183208 creator A5037320339 @default.
• W2119183208 date "2008-05-01" @default.
• W2119183208 modified "2023-09-23" @default.
• W2119183208 title "Stage II Adenocarcinoma of the Endometrium: Adjuvant Radiotherapy and Recurrence Patterns" @default.
• W2119183208 cites W1963592300 @default.
• W2119183208 cites W1963769544 @default.
• W2119183208 cites W1973301611 @default.
• W2119183208 cites W1978816129 @default.
• W2119183208 cites W1992321249 @default.
• W2119183208 cites W1992803488 @default.
• W2119183208 cites W1999037811 @default.
• W2119183208 cites W2001956598 @default.
• W2119183208 cites W2009160418 @default.
• W2119183208 cites W2020116318 @default.
• W2119183208 cites W2033825691 @default.
• W2119183208 cites W2043687307 @default.
• W2119183208 cites W2044500481 @default.
• W2119183208 cites W2074418301 @default.
• W2119183208 cites W2079856228 @default.
• W2119183208 cites W2086851106 @default.
• W2119183208 cites W2092470911 @default.
• W2119183208 cites W2098960933 @default.
• W2119183208 cites W2103072200 @default.
• W2119183208 cites W2103408844 @default.
• W2119183208 cites W2115897725 @default.
• W2119183208 cites W2147101451 @default.
• W2119183208 cites W2588207134 @default.
• W2119183208 cites W4237810254 @default.
• W2119183208 doi "https://doi.org/10.1016/j.ijrobp.2007.09.022" @default.
• W2119183208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18164851" @default.
• W2119183208 hasPublicationYear "2008" @default.
• W2119183208 type Work @default.
• W2119183208 sameAs 2119183208 @default.
• W2119183208 citedByCount "17" @default.
• W2119183208 countsByYear W21191832082014 @default.
• W2119183208 countsByYear W21191832082015 @default.
• W2119183208 countsByYear W21191832082016 @default.
• W2119183208 countsByYear W21191832082017 @default.
• W2119183208 countsByYear W21191832082018 @default.
• W2119183208 countsByYear W21191832082019 @default.
• W2119183208 countsByYear W21191832082020 @default.
• W2119183208 countsByYear W21191832082021 @default.
• W2119183208 countsByYear W21191832082022 @default.
• W2119183208 crossrefType "journal-article" @default.
• W2119183208 hasAuthorship W2119183208A5037320339 @default.
• W2119183208 hasConcept C121608353 @default.
• W2119183208 hasConcept C126322002 @default.
• W2119183208 hasConcept C126838900 @default.
• W2119183208 hasConcept C141071460 @default.
• W2119183208 hasConcept C143998085 @default.
• W2119183208 hasConcept C146357865 @default.
• W2119183208 hasConcept C151730666 @default.
• W2119183208 hasConcept C167135981 @default.
• W2119183208 hasConcept C2775908122 @default.
• W2119183208 hasConcept C2777088508 @default.
• W2119183208 hasConcept C2777416452 @default.
• W2119183208 hasConcept C2779742232 @default.
• W2119183208 hasConcept C509974204 @default.
• W2119183208 hasConcept C71924100 @default.
• W2119183208 hasConcept C86803240 @default.
• W2119183208 hasConceptScore W2119183208C121608353 @default.
• W2119183208 hasConceptScore W2119183208C126322002 @default.
• W2119183208 hasConceptScore W2119183208C126838900 @default.
• W2119183208 hasConceptScore W2119183208C141071460 @default.
• W2119183208 hasConceptScore W2119183208C143998085 @default.
• W2119183208 hasConceptScore W2119183208C146357865 @default.
• W2119183208 hasConceptScore W2119183208C151730666 @default.
• W2119183208 hasConceptScore W2119183208C167135981 @default.
• W2119183208 hasConceptScore W2119183208C2775908122 @default.
• W2119183208 hasConceptScore W2119183208C2777088508 @default.
• W2119183208 hasConceptScore W2119183208C2777416452 @default.
• W2119183208 hasConceptScore W2119183208C2779742232 @default.
• W2119183208 hasConceptScore W2119183208C509974204 @default.
• W2119183208 hasConceptScore W2119183208C71924100 @default.
• W2119183208 hasConceptScore W2119183208C86803240 @default.
• W2119183208 hasIssue "1" @default.
• W2119183208 hasLocation W21191832081 @default.
• W2119183208 hasLocation W21191832082 @default.
• W2119183208 hasOpenAccess W2119183208 @default.
• W2119183208 hasPrimaryLocation W21191832081 @default.
• W2119183208 hasRelatedWork W2043597413 @default.
• W2119183208 hasRelatedWork W2055348823 @default.
• W2119183208 hasRelatedWork W2123312949 @default.
• W2119183208 hasRelatedWork W2616037512 @default.
• W2119183208 hasRelatedWork W2788839829 @default.
• W2119183208 hasRelatedWork W2966036943 @default.
• W2119183208 hasRelatedWork W3029213237 @default.
• W2119183208 hasRelatedWork W3107045007 @default.
• W2119183208 hasRelatedWork W4205904040 @default.
• W2119183208 hasRelatedWork W4206581437 @default.
• W2119183208 hasVolume "71" @default.
• W2119183208 isParatext "false" @default.
• W2119183208 isRetracted "false" @default.
• W2119183208 magId "2119183208" @default.
• W2119183208 workType "article" @default.